Patents by Inventor Maria Herva

Maria Herva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12123059
    Abstract: The present invention refers to an in vitro method for predicting cardiotoxicity risk in a cancer patient receiving, or susceptible to receive, anthracyclines chemotherapy based on the determination of the expression levels of a combination of 10 circulating miRNAs consisting of miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p and miRNA-4732-3p, in a biological sample isolated from the patient. The present invention also refers to said set of 10 circulating miRNAs for its use as biomarker of prediction of cardiotoxicity risk in cancer patients receiving, or susceptible to receive, anthracyclines chemotherapy. Finally, a method for the prevention of cardiotoxicity, in patients receiving or susceptible to receive anthracyclines chemotherapy, that comprises modulating the expression levels of the set of said 10 circulating miRNAS is contemplated.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: October 22, 2024
    Assignees: Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana, Maastricht University
    Inventors: David Hervàs Marin, Ana Santaballa Beltràn, Carmen Salvador Coloma, Rubèn Carrero Garcìa, Rafael Sanchez Sanchez, Akaitz Dorronsoro Gonzàlez, Imelda Ontoria Oviedo, Sandra Tejedor Gascòn, Estaban Peiró Molina, Amparo Hernándiz Martinez, Hernán González-King, María Ciria Calduch, Delia Castellano Izquierdo, Joaquín Panadero Romero, Jose Anastasio Montero Argudo, Pilar Sepúlveda Sanchis, Nahuel A. García, Florian Caiment, Jos Kleinjans, Stephane Heymans, Jort Merken
  • Patent number: 12076406
    Abstract: In some embodiments, the disclosure provides for a conjugate comprising: a) a peptide that competes with an Fc fragment of an IgG for binding to an Fc receptor; and b) a targeting moiety that targets molecular aggregates. In some embodiments, the disclosure provides for methods of using the conjugates for treating a disease or disorder associated with aggregate formation.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: September 3, 2024
    Assignee: MEDIMMUNE LIMITED
    Inventors: Damian C. Crowther, Maria Herva, Roland Bürli, Lutz Jermutus
  • Publication number: 20220001016
    Abstract: In some embodiments, the disclosure provides for a conjugate comprising: a) a peptide that competes with an Fc fragment of an IgG for binding to an Fc receptor; and b) a targeting moiety that targets molecular aggregates. In some embodiments, the disclosure provides for methods of using the conjugates for treating a disease or disorder associated with aggregate formation.
    Type: Application
    Filed: June 17, 2021
    Publication date: January 6, 2022
    Inventors: Damian C. Crowther, Maria Herva, Roland Bürli, Lutz Jermutus
  • Patent number: 11065336
    Abstract: In some embodiments, the disclosure provides for a conjugate comprising: a) a peptide that competes with an Fc fragment of an IgG for binding to an Fc receptor; and b) a targeting moiety that targets molecular aggregates. In some embodiments, the disclosure provides for methods of using the conjugates for treating a disease or disorder associated with aggregate formation.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: July 20, 2021
    Assignee: MEDIMMUNE LIMITED
    Inventors: Damian C. Crowther, Maria Herva, Roland Bürli, Lutz Jermutus
  • Publication number: 20190328889
    Abstract: In some embodiments, the disclosure provides for a conjugate comprising: a) a peptide that competes with an Fc fragment of an IgG for binding to an Fc receptor; and b) a targeting moiety that targets molecular aggregates. In some embodiments, the disclosure provides for methods of using the conjugates for treating a disease or disorder associated with aggregate formation.
    Type: Application
    Filed: April 29, 2019
    Publication date: October 31, 2019
    Inventors: Damian C. Crowther, Maria Herva, Roland Bürli, Lutz Jermutus